{"id":32261,"date":"2025-04-23T14:17:35","date_gmt":"2025-04-23T06:17:35","guid":{"rendered":"https:\/\/flcube.com\/?p=32261"},"modified":"2025-04-23T14:17:36","modified_gmt":"2025-04-23T06:17:36","slug":"ascletis-pharma-announces-positive-phase-ib-results-for-asc30-in-obesity-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32261","title":{"rendered":"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment"},"content":{"rendered":"\n

China-based Ascletis Pharma Inc. (HKG: 1672<\/a>) has announced positive top-line results from a Phase Ib multiple ascending dose (MAD) study for its investigational GLP-1R biased small molecule agonist, ASC30. The study was conducted in the US among participants with obesity (BMI: 30-40 kg\/m\u00b2). These results highlight the potential of ASC30 as a promising treatment option for obesity.<\/p>\n\n\n\n

ASC30: Unique Administration Flexibility<\/strong>
ASC30 is a novel chemical entity (NCE) with U.S. and global compound patent protection until 2044. A key feature of ASC30 is its unique administration flexibility, allowing it to be formulated as both an oral tablet and a subcutaneous injection. This versatility enhances its potential as a versatile treatment option for obesity.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
In the study, participants who received ASC30 orally once daily for four weeks with weekly dose escalation (2 mg, 10 mg, 20 mg, and 40 mg) experienced an average body weight reduction of 6.5% relative to baseline after placebo calibration. Another cohort, receiving ASC30 at doses of 2 mg, 5 mg, 10 mg, and 20 mg, showed an average body weight reduction of 4.5%. Notably, no vomiting was reported in the 40 mg dose group. These results support the safety and efficacy profile of ASC30.<\/p>\n\n\n\n

Future Development<\/strong>
The positive tolerability and efficacy data from the Phase Ib study have informed the design of a 13-week Phase IIa study for ASC30 as an oral once-daily tablet. The study protocol has been submitted to the U.S. Food and Drug Administration (FDA), adopting a “lower starting dose and slower titration” strategy.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib…<\/p>\n","protected":false},"author":1,"featured_media":32262,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[189,17,980,86],"class_list":["post-32261","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ascletis-pharma","tag-clinical-trial-results","tag-hkg-1672","tag-obesity"],"yoast_head":"\nAscletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib multiple ascending dose (MAD) study for its investigational GLP-1R biased small molecule agonist, ASC30. The study was conducted in the US among participants with obesity (BMI: 30-40 kg\/m\u00b2). These results highlight the potential of ASC30 as a promising treatment option for obesity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32261\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment\" \/>\n<meta property=\"og:description\" content=\"China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib multiple ascending dose (MAD) study for its investigational GLP-1R biased small molecule agonist, ASC30. The study was conducted in the US among participants with obesity (BMI: 30-40 kg\/m\u00b2). These results highlight the potential of ASC30 as a promising treatment option for obesity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32261\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-23T06:17:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T06:17:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2303.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32261#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32261\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment\",\"datePublished\":\"2025-04-23T06:17:35+00:00\",\"dateModified\":\"2025-04-23T06:17:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32261\"},\"wordCount\":261,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32261#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2303.webp\",\"keywords\":[\"Ascletis Pharma\",\"Clinical trial results\",\"HKG: 1672\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32261#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32261\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32261\",\"name\":\"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32261#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32261#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2303.webp\",\"datePublished\":\"2025-04-23T06:17:35+00:00\",\"dateModified\":\"2025-04-23T06:17:36+00:00\",\"description\":\"China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib multiple ascending dose (MAD) study for its investigational GLP-1R biased small molecule agonist, ASC30. The study was conducted in the US among participants with obesity (BMI: 30-40 kg\\\/m\u00b2). These results highlight the potential of ASC30 as a promising treatment option for obesity.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32261#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32261\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32261#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2303.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2303.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32261#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment - Insight, China's Pharmaceutical Industry","description":"China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib multiple ascending dose (MAD) study for its investigational GLP-1R biased small molecule agonist, ASC30. The study was conducted in the US among participants with obesity (BMI: 30-40 kg\/m\u00b2). These results highlight the potential of ASC30 as a promising treatment option for obesity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32261","og_locale":"en_US","og_type":"article","og_title":"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment","og_description":"China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib multiple ascending dose (MAD) study for its investigational GLP-1R biased small molecule agonist, ASC30. The study was conducted in the US among participants with obesity (BMI: 30-40 kg\/m\u00b2). These results highlight the potential of ASC30 as a promising treatment option for obesity.","og_url":"https:\/\/flcube.com\/?p=32261","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-23T06:17:35+00:00","article_modified_time":"2025-04-23T06:17:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2303.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32261#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32261"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment","datePublished":"2025-04-23T06:17:35+00:00","dateModified":"2025-04-23T06:17:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32261"},"wordCount":261,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32261#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2303.webp","keywords":["Ascletis Pharma","Clinical trial results","HKG: 1672","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32261#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32261","url":"https:\/\/flcube.com\/?p=32261","name":"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32261#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32261#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2303.webp","datePublished":"2025-04-23T06:17:35+00:00","dateModified":"2025-04-23T06:17:36+00:00","description":"China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib multiple ascending dose (MAD) study for its investigational GLP-1R biased small molecule agonist, ASC30. The study was conducted in the US among participants with obesity (BMI: 30-40 kg\/m\u00b2). These results highlight the potential of ASC30 as a promising treatment option for obesity.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32261#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32261"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32261#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2303.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2303.webp","width":1080,"height":608,"caption":"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32261#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2303.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32261"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32261\/revisions"}],"predecessor-version":[{"id":32263,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32261\/revisions\/32263"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32262"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}